Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers a precision marketing and corporate solution encompassing a wide array of services. These include project oversight, clinical supervision, handling of clinical data, biostatistical analysis, drafting of study protocols, medical supervision, patient enrollment, and system support. Furthermore, it offers digital market intelligence, electronic data collection, real-world evidence generation, and the development of application software. Medlive also provides a medical knowledge solution focused on continuing medical education and tools for clinical decision-making, which involves licensing specialized software to physicians and other registered users, including various healthcare practitioners and pharmaceutical corporations. An intelligent patient management solution is another core offering, delivering chronic disease management services that cover online consultations, prescription fulfillment, and patient care facilitated by an Internet hospital. Additionally, it provides condition-specific patient education, involving the creation of content, development of specialized software, and associated support services. Originally established in 1996 as Kingyee Co., Limited, the enterprise adopted the name Medlive Technology Co., Ltd. in 2021. Its corporate headquarters are located in Beijing, China.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,
Target Price
The average target price of 2192.HK is 11.0 and suggests 66.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i